ABSTRACT: Background. Intraoperative identification of parathyroid adenomas can be challenging. We hypothesized that low-doses methylene blue (MB) and near-infrared fluorescence (NIRF) imaging could be used to identify parathyroid adenomas intraoperatively. Methods. MB was injected intravenously after exploration at a dose of 0.5 mg/kg into 12 patients who underwent parathyroid surgery. NIRF imaging was performed using the Mini-FLARE imaging system. Results. In 10 of 12 patients, histology confirmed a parathyroid adenoma. In 9 of these patients, NIRF could clearly identify the parathyroid adenoma during surgery. Seven of these 9 patients had a positive preoperative 99m Tc-sestamibi single photon emission CT (SPECT) scan. Importantly, in 2 patients, parathyroid adenomas could be identified only using NIRF. Conclusion. This is the first study to show that low-dose MB can be used as NIRF tracer for identification of parathyroid adenomas, and suggests a correlation with preoperative 99m Tc-sestamibi SPECT scanning.
INTRODUCTION
Primary hyperparathyroidism is a common endocrine disorder caused by overproduction of parathyroid hormone (PTH) by adenomatous or hyperplastic parathyroid glands. In patients with hyperparathyroidism, resection of these glands is the only curative treatment. The wide variability of the anatomic location, shape, and number of parathyroid glands makes successful parathyroid surgery challenging. Various preoperative imaging modalities contribute to detailed surgical planning, which is particularly important when using a minimally invasive surgical approach. [1] [2] [3] Currently, a combination of a cervical ultrasonography and a 99m Tc-sestamibi planar scan, whether or not combined with a single-photon emission CT (SPECT) 3D scan, is most often used for preoperative localization. However, only few intraoperative imaging modalities are available. Despite that the current success rate of parathyroidectomy exceeds 95% without any intraoperative imaging adjuncts in the hands of experienced surgeons, 1, 4 intraoperative imaging tools could aid in the localization of difficult localized parathyroid adenoma and, in addition, possibly reduce time of surgery. 5 For intraoperative localization, radio-guided parathyroidectomy using 99m Tc-sestamibi has been reported. 6, 7 This technique, however, lacks real-time visual information. High-dose methylene blue (MB), used as a blue dye, was introduced by Dudley 8 in 1971 and others 6, 9, 10 for the intraoperative identification of parathyroid adenomas by a simple peripheral infusion, reporting sensitivity and specificity of 79% and 93%, respectively. 10, 11 However, a major disadvantage of using MB is that the high dose (7.5 mg/kg) required for visualization of blue color by the human eye brings a substantial risk of serious adverse events, such as toxic metabolic encephalopathy. 12 fluorescence and aminolevulinic acid (ALA) to identify parathyroid glands, which was successfully tested in clinical studies. [13] [14] [15] However, ALA can cause phototoxic reactions for which patients have to be shielded from direct light exposure for 48 hours. Furthermore, subsurface detectability using ALA is minimal because of high absorption and scatter of visible light in living tissue. Therefore, novel and improved intraoperative imaging modalities to aid the surgeon in localization of the parathyroid glands are needed during parathyroid surgery.
Near-infrared fluorescence (NIRF) imaging is a promising technique that also facilitates intraoperative, real-time, visual information. [16] [17] [18] This technique is based on the use of exogenous NIRF contrast agents that can be detected by intraoperative imaging systems to visualize specific tissues. Advantages of this technique are its high sensitivity and high tissue penetration of approximately 5 mm. As such, it has wide applications, including sentinel lymph node mapping in several tumor types. [19] [20] [21] [22] MB, which was used for parathyroid adenoma identification, as stated above, has the advantageous property that it becomes a moderate-strength fluorophore emitting at approximately 700 nm when diluted to levels that are almost undetectable to the human eye. When lower doses of MB can still provide clear identification of parathyroid adenomas using NIRF, this could significantly reduce the risk for adverse events. 23 The purpose of this study was to assess feasibility of using low-dose MB for intraoperative NIRF-guided detection of parathyroid adenomas. Furthermore, the concordance between preoperative 99m Tcsestamibi-SPECT scanning and intraoperative NIRF was preliminarily assessed.
MATERIALS AND METHODS

Clinical study
This study was approved by the Medical Ethics Committee of the Leiden University Medical Center and was performed in accordance with the ethical standards of the Helsinki Declaration of 1975. All patients planning to undergo a resection of a parathyroid adenoma for primary hyperparathyroidism or parathyromatosis were eligible for participation in the study. Exclusion criteria were pregnancy or lactation, the use of serotonin reuptake inhibitors, serotonin, noradrenalin reuptake inhibitors and/or tricyclic antidepressants, severe renal failure, G6PD-deficiency, or an allergy to MB. All patients gave informed consent and were anonymized. Patients received standard of care diagnostic workup, which for our center implied a preoperative 99m Tc-sestamibi-SPECT that was sometimes combined with a low-dose CT scan for preoperative surgical planning. If indicated, a preoperative cervical ultrasonography was performed. After subplatysmal dissection, retraction, draping, and initial surgical exploration of the suspected parathyroid adenoma in the neck region, 0.5 mg/kg of MB (concentration 10 mg/mL) was infused intravenously over 5 minutes. Subsequently, NIRF imaging of the neck region was performed using the Mini-FLARE NIRF imaging system, which has been described previously. 20 In 1 patient, a thoracotomy was performed after SPECT-CT localization of the parathyroid adenoma in pericardium. After resection of the putative parathyroid adenoma, an intraoperative PTH assay was performed. Postoperative histopathological examination was obtained, which served as the gold standard for parathyroid adenoma identification. Parathyroid tissue was snap frozen and sectioned at 10 lm for fluorescence microscopy.
Fluorescence microscopy
Snap frozen tissue was sectioned at 10 lm for fluorescence microscopy, which was performed on a Zeiss LSM 700 Confocal Laser Scanning Microscope and a Zeiss HBO 100 Microscope Illuminating System (Jena, Germany) using a 633 nm laser for excitation and a 650 nm high pass emission filter. Subsequently, tissue sections were stained with hematoxylin-eosin.
Statistical analysis
For statistical analysis, SPSS statistical software package (version 16.0, Chicago, IL) was used. Signal-tobackground ratios (SBRs) were calculated by dividing the fluorescent signal in the parathyroid adenoma by fluorescent signal of surrounding healthy tissue. Patient age and body mass index (BMI) were reported in median and range and SBR was reported in mean and SD. To compare fluorescent signal in the parathyroid adenoma with fluorescent signal in the thyroid gland, the independent-sample t test was used. Any p < .05 was considered significant.
RESULTS
Study subjects
Patient characteristics and histological results of the 12 patients included are listed in Table 1 . Median patient age was 58 years (range, 17-78 years), median BMI was 26 (range, 18-34 kg/m 2 ). Eleven patients were planned for surgery for primary hyperparathyroidism and 1 patient had parathyromatosis. Prior to the study, 1 patient underwent a total thyroid resection, 1 patient had a parathyroid adenoma resection, and 1 patient had undergone previous parathyroid surgery 3 times as well as a thymectomy. During the current study, a resection of the putative diseased tissue was performed in all patients.
Histopathological examination showed a solitary parathyroid adenoma in 7 patients, 2 parathyroid adenomas in 1 patient, small parathyroid fragments in 1 patient, a parathyroid carcinoma in 1 patient, and a thyroid carcinoma with a synchronous parathyroid adenoma in 2 patients. Average maximum diameter of the resected lesions was 15.7 6 8.7 mm.
Preoperative imaging
In all patients, a preoperative 99m Tc-sestamibi-SPECT scan was performed, which was combined with a low-dose CT scan in 10 patients. In 8 of 12 patients, the 99m Tc-sestamibi-SPECT scan could identify the parathyroid adenoma. In 9 of 12 patients, a preoperative ultrasonography was performed, which was positive in 4 patients. Preoperative imaging results are summarized in Table 2 .
Intraoperative near-infrared fluorescence imaging
Intraoperative NIRF guidance was provided by the Mini-FLARE Imaging System and MB, which clearly identified a hyperparathyroid adenoma in 9 patients (Figures 1 and  2 ). Of these patients, the average SBR was 6.1 6 4.1. Importantly, in 2 of these 9 NIRF-positive patients, the parathyroid adenoma was not identified using the 99m Tcsestamibi-SPECT scan or preoperative ultrasound. In 3 of 12 patients, no intraoperative fluorescent signal could be detected. In 2 of these patients, no parathyroid adenoma was found during histological examination (parathyromatosis and a necrotic parathyroid carcinoma). In 1 patient a normal parathyroid adenoma, which contained extensive fibrosis and bleeding, was identified. In other words, in 9 of 10 patients diagnosed with a parathyroid adenoma, the adenoma could be identified using NIRF. No significant difference was observed between parathyroid fluorescence and thyroid fluorescence (322.6 6 272.1 vs 220.2 6 186.7; p 5 .25). During the course of the study, no adverse events were observed.
In 9 of 12 patients, preoperative results using 99m
Tc-sestamibi overlapped with intraoperative NIRF. In 1 patient in whom the 99m Tc-sestamibi-scan was positive, no fluorescent signal could be obtained. This patient was found to have a Tc-sestamibi-scan was negative, NIRF could identify the parathyroid adenoma. In 3 of 9 patients in whom an ultrasonography was performed, results overlapped with NIRF. The overlap between different imaging modalities and the location of the parathyroid glands is schematically shown in Figure 3 .
Fluorescence microscopy
Seven hundred NIRF signals of MB was located within oncocytic cells as confirmed using hematoxylin-eosin staining of the same specimen (Figure 4 ).
DISCUSSION
The primary objective of the current study was to test the feasibility of NIRF with low-dose MB (0.5 mg/kg; 15 times lower than the dose used for macroscopic identification) to identify parathyroid adenomas during surgery. Furthermore, concordance between 99m Tc-sestamibi SPECT and intraoperative NIRF imaging results was assessed. Two patients were not diagnosed with a parathyroid adenoma. A clear identification of parathyroid adenomas using NIRF was found in 9 of 10 patients who were histologically diagnosed with a parathyroid adenoma. Furthermore, a high overlap between imaging results of 99m Tc-sestamibi SPECT and NIRF was observed.
In 3 of 12 patients, no clear identification of the lesion could be obtained using NIRF. In 1 of these patients, histopathological examination revealed a parathyroid carcinoma. This carcinoma was described as a highly necrotic lesion, which presumably hampered MB uptake in this lesion. Alternatively, carcinoma may not take up MB like benign lesions. One patient had extended cervical parathyromatosis and all parathyroid glands were already surgically removed in the past. In this patient, the parathyroid tissue could not be demarcated from the surrounding tissue; however, no adenomas were present. In 1 patient with a large parathyroid adenoma in whom no adequate SBR could be obtained, the adenoma contained extensive fibrosis and bleeding. The extensive fibrosis and bleeding could have hampered uptake of MB in the adenoma, which might also explain the negative 99m Tcsestamibi SPECT scan.
A potential pitfall using the technology we describe is the background signal in the thyroid gland. It is known from data acquired in patients undergoing 99m Tc-sestamibi radioscintigraphy that adenomatous and hyperplastic parathyroid tissue show more avid uptake of 99m Tc-sestamibi, although initially this activity can be obscured by uptake from the adjacent thyroid gland. The observation that abnormal parathyroid tissue commonly retains 99m Tcsestamibi longer than thyroid gland tissue has led to the widespread use of delayed imaging. 24 Therefore, an early (15-30 minute) and delayed (2-3 hour) imaging sequence is performed. Furthermore, a window of 4 hours between administration and imaging was also used in the clinical studies that used ALA for parathyroid identification. 13, 15 In the current study, high thyroid gland uptake of MB was observed. We hypothesize that a similar delayed imaging protocol could improve the contrast between thyroid gland and parathyroid gland tissue.
Although conventional preoperative imaging modalities ( 99m Tc-sestamibi scan and ultrasonography) achieve an accurate preoperative localization of the adenoma in most cases (sensitivity approximately 80% for both techniques), intraoperative identification can be challenging. 25 In this perspective, time needed to intraoperatively localize the adenoma may decrease using NIRF and MB. The comparable biological characteristics of MB and sestamibi, both lipophilic and cationic, resulted in a high concordance between the outcome of 99m Tc-sestamibi scans and NIRF detection in 7 of 9 patients in the current study. The results of the 99m Tc-sestamibi SPECT-CT may therefore help predict those patients that will most likely benefit from NIRF intraoperative imaging.
The current study was the first to show that low-dose MB and NIRF can be used for the intraoperative detection of parathyroid adenomas after a simple peripheral infusion. However, this technique will not replace the detailed and thorough anatomic knowledge and experience of surgeons, which are the key factors for successful parathyroidectomy. Because of the significantly lower doses of MB that can be used, this technique can provide valuable additional information during surgery in a safe manner, provided that proper exclusion criteria are followed. However, optimization of MB dose, timing of injection, clinical outcome, and patient benefit need to be studied in larger clinical trials.
